263 related articles for article (PubMed ID: 29895969)
21. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E
Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799
[TBL] [Abstract][Full Text] [Related]
22. Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers.
Ganguly R; Hong CS; Smith LG; Kornblum HI; Nakano I
Mol Cancer Ther; 2014 Jun; 13(6):1393-8. PubMed ID: 24795222
[TBL] [Abstract][Full Text] [Related]
23. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
[TBL] [Abstract][Full Text] [Related]
24. Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer.
Wang J; Wang Y; Shen F; Xu Y; Zhang Y; Zou X; Zhou J; Chen Y
Cancer Med; 2018 Nov; 7(11):5665-5678. PubMed ID: 30334367
[TBL] [Abstract][Full Text] [Related]
25. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.
Chlenski A; Park C; Dobratic M; Salwen HR; Budke B; Park JH; Miller R; Applebaum MA; Wilkinson E; Nakamura Y; Connell PP; Cohn SL
Mol Cancer Ther; 2019 Mar; 18(3):507-516. PubMed ID: 30674566
[TBL] [Abstract][Full Text] [Related]
26. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
[TBL] [Abstract][Full Text] [Related]
27. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
[TBL] [Abstract][Full Text] [Related]
28. MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells.
Beke L; Kig C; Linders JT; Boens S; Boeckx A; van Heerde E; Parade M; De Bondt A; Van den Wyngaert I; Bashir T; Ogata S; Meerpoel L; Van Eynde A; Johnson CN; Beullens M; Brehmer D; Bollen M
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26431963
[TBL] [Abstract][Full Text] [Related]
29. Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors.
Zhou S; Li GB; Luo L; Zhong L; Chen K; Li H; Jiang XJ; Fu Q; Long X; Bao JK
Org Biomol Chem; 2018 Feb; 16(9):1489-1495. PubMed ID: 29411820
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2016 Apr; 7(14):18171-82. PubMed ID: 26918358
[TBL] [Abstract][Full Text] [Related]
31. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
32. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
Edupuganti R; Taliaferro JM; Wang Q; Xie X; Cho EJ; Vidhu F; Ren P; Anslyn EV; Bartholomeusz C; Dalby KN
Bioorg Med Chem; 2017 May; 25(9):2609-2616. PubMed ID: 28351607
[TBL] [Abstract][Full Text] [Related]
35. MELK is not necessary for the proliferation of basal-like breast cancer cells.
Huang HT; Seo HS; Zhang T; Wang Y; Jiang B; Li Q; Buckley DL; Nabet B; Roberts JM; Paulk J; Dastjerdi S; Winter GE; McLauchlan H; Moran J; Bradner JE; Eck MJ; Dhe-Paganon S; Zhao JJ; Gray NS
Elife; 2017 Sep; 6():. PubMed ID: 28926338
[TBL] [Abstract][Full Text] [Related]
36. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.
Pitner MK; Taliaferro JM; Dalby KN; Bartholomeusz C
Expert Opin Ther Targets; 2017 Sep; 21(9):849-859. PubMed ID: 28764577
[TBL] [Abstract][Full Text] [Related]
37. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells.
Moon EY; Lerner A
Cancer Res; 2002 Oct; 62(20):5711-9. PubMed ID: 12384529
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
39. MELK is a novel therapeutic target in high-risk neuroblastoma.
Guan S; Lu J; Zhao Y; Yu Y; Li H; Chen Z; Shi Z; Liang H; Wang M; Guo K; Chen X; Sun W; Bieerkehazhi S; Xu X; Sun S; Agarwal S; Yang J
Oncotarget; 2018 Jan; 9(2):2591-2602. PubMed ID: 29416794
[TBL] [Abstract][Full Text] [Related]
40. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]